You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 8,436,149

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,436,149

Title:	Crystalline anti-hTNFalpha antibodies
Abstract:	The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
Inventor(s):	Borhani; David W. (Hartsdale, NY), Fraunhofer; Wolfgang (Newton, MA), Krause; Hans-Juergen (Gruenstadt, DE), Koenigsdorfer; Anette (Ilvesheim, DE), Winter; Gerhard (Penzberg, DE), Gottschalk; Stefan (Grunwald, DE)
Assignee:	AbbVie Biotechnology Ltd (Hamilton, BM)
Application Number:	13/225,281
Patent Claims:	1. A crystal of an IgG human anti-hTNFalpha antibody comprising two heavy chains each with a molecular weight of about 50 kDa and comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2, wherein said crystal has a needle morphology with a length of about 2-500 .mu.m and an l/d ratio of about 3 to 30. 2. The crystal according to claim 1, wherein said antibody is selected from the group consisting of: IgG1, IgG2, IgG3 and IgG4 antibodies. 3. The crystal according to claim 1, wherein said antibody is an IgG1 antibody. 4. The crystal according to claim 1, wherein the antibody is adalimumab (D2E7). 5. A pharmaceutical composition comprising: (a) crystals of an anti-hTNFalpha antibody according to claim 1, and (b) at least one pharmaceutical excipient; wherein the composition is provided as a solid, semisolid or liquid formulation, each formulation containing said antibody in crystalline form. 6. A pharmaceutical composition comprising: (a) crystals of an anti-hTNFalpha antibody according to claim 1, and (b) at least one pharmaceutical excipient, which embeds or encapsulates crystals of said antibody. 7. The composition according to claim 5, wherein said composition has an antibody concentration greater than about 1 mg/ml. 8. The composition according to claim 5, wherein said composition has an antibody concentration greater than about 200 mg/ml. 9. The composition according to claim 5, wherein said excipient comprises at least one polymeric optionally biodegradable carrier or at least one oil or lipid carrier. 10. The composition according to claim 9, wherein said polymeric carrier is a polymer selected from one or more of the group consisting of: poly (acrylic acid), poly (cyanoacrylates), poly (amino acids), poly (anhydrides), poly (depsipeptide), poly (esters), poly (lactic acid), poly (lactic-co-glycolic acid) or PLGA, poly (.beta.-hydroxybutryate), poly (caprolactone), poly (dioxanone); poly (ethylene glycol), poly (hydroxypropyl) methacrylamide, poly (organo) phosphazene, poly (ortho esters), poly (vinyl alcohol), poly (vinylpyrrolidone), maleic anhydride alkyl vinyl ether copolymers, pluronic polyols, albumin, alginate, cellulose and cellulose derivatives, collagen, fibrin, gelatin, hyaluronic acid, oligosaccharides, glycaminoglycans, sulfated polysaccharides, blends and copolymers thereof. 11. An injectable liquid composition comprising anti-hTNFalpha antibody crystals according to claim 1 and having an antibody concentration in the range of about 10 to 400 mg/ml. 12. A crystal slurry comprising anti-hTNFalpha antibody crystals according to claim 1, having an antibody concentration greater than about 100 mg/ml. 13. A batch crystallization method for crystallizing an anti-hTNFalpha antibody, comprising the steps of: (a) providing an aqueous solution of said antibody in admixture with an inorganic phosphate salt as a crystallization agent to obtain an aqueous crystallization mixture, wherein the aqueous crystallization mixture has a pH of about 3 to about 5; and (b) incubating said aqueous crystallization mixture until crystals of said antibody are formed, wherein the anti-hTNFalpha antibody is an IgG human anti-hTNFalpha antibody comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2, and wherein said crystal has a needle morphology with a length of about 2-500 .mu.m and an l/d ratio of about 3 to 30. 14. The crystallization method according to claim 13, wherein said aqueous crystallization mixture contains a buffer. 15. The crystallization method according to claim 14, wherein said buffer comprises an acetate buffer. 16. The crystallization method according to claim 15, wherein the buffer comprises sodium acetate. 17. The crystallization method according to claim 14, wherein the buffer concentration in said aqueous crystallization mixture is about 0 M to about 0.5 M. 18. The crystallization method according to claim 15, wherein the buffer concentration in said aqueous crystallization mixture is about 0 M to about 0.5 M. 19. The crystallization method according to claim 16, wherein the buffer concentration in said aqueous crystallization mixture is about 0 M to about 0.5 M. 20. The crystallization method according to claim 13, wherein the phosphate salt is a hydrogenphosphate salt. 21. The crystallization method according to claim 13, wherein the phosphate salt is an alkali metal salt, or a mixture of at least two different alkali metal salts. 22. The crystallization method according to claim 13, wherein the phosphate salt concentration in the crystallization mixture is in the range of about 1 to 6 M. 23. The crystallization method according to claim 22, wherein the salt concentration in the crystallization mixture is in the range of about 1.0 to 3.0 M. 24. The crystallization method according to claim 13, wherein at least one of the following additional crystallization conditions are met: a) incubation is performed for between about 1 hour to about 60 days; b) incubation is performed at a temperature between about 4.degree. C. and about 37.degree. C; c) the antibody concentration is in the range of about 0.5 to about 100 mg/ml. 25. The crystallization method according to claim 24, further comprising the step of drying said crystals. 26. The crystallization method according to claim 24, further comprising the step of exchanging a crystallization mother liquor with a different buffer. 27. The crystallization method according to claim 24, wherein the batch comprises a batch volume in the range of about 1 ml to about 20,000 liters.

Details for Patent 8,436,149

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002	⤷ Try a Trial	2026-10-27
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008	⤷ Try a Trial	2026-10-27
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013	⤷ Try a Trial	2026-10-27
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.